2022 Top Story in Neurology: Multiple Sclerosis—The Tale of Two Viruses
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Etimadefar M, Nouri H, Pitzalis M, et al. Multiple Sclerosis Disease-Modifying Therapies and COVID-19 Vaccines: A Practical Review and Meta-Analysis. J Neurol Neurosurg Psychiatry. 2022;93(9):986-994.
- van Kempen ZLE, Hogenboom L, Toorop AA, et al. Ocrelizumab Concentration Is a Good Predictor of SARS-CoV-2 Vaccination Response in Patients with Multiple Sclerosis. Ann Neurol. 2022 Oct 17. doi: 10.1002/ana.26534. Online ahead of print.
- PracticeUpdate Editorial Team. ECTRIMS 2022: Use of Some Disease-Modifying Therapies in Multiple Sclerosis Associated With Increased Risk for COVID-19. PracticeUpdate Multiple Sclerosis. 2022 Nov 9. Accessed 11/22/22.
- Woopen C, Dunsche M, Haase R, et al. Timing of SARS-CoV-2 Vaccination Matters in People With Multiple Sclerosis on Pulsed Anti-CD20 Treatment. Neurol Neuroimmunol Neuroinflamm. 2022;9(6):e20031.
- Kim JE, Park J, Song TJ. A Disproportionality Analysis for the Association of Central Nervous System Demyelinating Diseases With COVID-19 Vaccination Using the World Health Organization Pharmacovigilance Database. Mult Scler. 2022;28(13):2112-2123.
- Bjornevik K, Cortese M, Healy B, et al. Longitudinal Analysis Reveals High Prevalence of Epstein-Barr Virus Associated With Multiple Sclerosis. Science. 2022;375(6578):296-301.
- Lanz TV, Brewer RC, Ho PP, et al. Clonally Expanded B Cells in Multiple Sclerosis Bind EBV EBNA1 and GlialCAM. Nature. 2022;603(7900):321-327.
Disclosure statements are available on the authors' profiles: